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Background. Controversy surrounds the decision to adopt the International Association of Diabetes and Pregnancy Study Groups
(IADPSG) criteria for the diagnosis of gestational diabetes mellitus (GDM) as fears that disease prevalence rates will soar have
been raised. Aims. To investigate the prevalence of pregnancy complicated with GDM before and after the introduction of the
IADPSG 2010 diagnostic criteria. Materials and Methods. A prospective audit of all women who delivered from July 1, 2010, to
June 30, 2014, in a predefined geographic region within the North Metropolitan Health Service of Western Australia. Women were
diagnosed with GDM according to Australian Diabetes in Pregnancy Society (ADIPS 1991) criteria until December 31, 2011, and by
the IADPSG 2010 criteria after this date. Incidence of GDM and predefined pregnancy outcomes were audited. Results. Of 10,296
women, antenatal oral glucose tolerance test (OGTT) results and follow-up data were obtained for 10,103 women (98%), of whom
349 (3.5%) were diagnosed with GDM.The rate of GDMutilising ADIPS criteria was 3.4% and the rate of utilising IADPSG criteria
was 3.5% (𝑝 = 0.92). Conclusion. IADPSG diagnostic criteria did not significantly increase the incidence of GDM in this low
prevalence region.
1. Introduction
Gestational diabetes mellitus (GDM) is a common medical
complication of pregnancy defined as “any degree of glucose
intolerance with onset or first recognition during pregnancy”
[1, 2]. The initial criteria for diagnosis were established
more than 40 years ago [3]; however, these criteria did
not necessarily identify pregnancies with increased risk of
adverse pregnancy outcome [4].
The hyperglycaemia and adverse pregnancy outcome
(HAPO) study was conducted to clarify the associations
between maternal hyperglycaemia and adverse outcomes.
The study showed associations between increasing levels
of fasting blood glucose (FBG), 1-hour and 2-hour plasma
glucose obtained following an oral glucose tolerance test
(OGTT), and birthweight >90th centile and cord-blood
serum C-peptide level >90th centile [5]. The secondary
outcomes of premature delivery, shoulder dystocia or birth
injury, admission to intensive neonatal care unit, hyperbiliru-
binemia, and preeclampsia were also increased by maternal
hyperglycaemia [5].
The consideration of HAPO data led to a recommen-
dation in 2010 by the International Association of Diabetes
and Pregnancy Study Groups (IADPSG) for the FBG and 1 h
and 2 h glucose levels to diagnose GDM [4]. The diagnostic
threshold values were the average glucose values at which
the odds for birthweight >90th centile, cord C-peptide >90th
centile, and percent body fat >90th centile reached 1.75 times
the estimated odds of the outcomes at mean glucose values
[4, 5].
However, concern has been expressed that adoption of
the new diagnostic criteria would lead to a dramatic increase
in the incidence of GDM. One Australian study reported
that the change in diagnostic criteria from the previously
Hindawi Publishing Corporation
Journal of Pregnancy
Volume 2015, Article ID 754085, 5 pages
http://dx.doi.org/10.1155/2015/754085
2 Journal of Pregnancy
utilised Australasian Diabetes in Pregnancy Society (ADIPS)
1999 criteria [6] to the new IADPSG 2010 criteria [4] would
increase the prevalence of GDM from 9.6% to 13.0% [7].
A NZ study reported that the incidence might rise from
6% to 10% [8]. National debate continues on the workforce
implications of the revised criteria and their clinical impact
[9, 10].
The aim of this study was to audit the impact of the
change from the ADIPS 1999 criteria [6] to the IADPSG
2010 diagnostic criteria [4] within a geographically defined
region.
2. Methods
A prospective audit of all pregnancies diagnosed with GDM
commenced from July 1, 2010, following publication ofHAPO
and the IADPSG recommendations. The Institutional Ethics
Committee determined that the project fulfilled the criteria of
an audit project as pregnancy outcomes were being audited
and no intervention other than routine care according to
existing clinical protocols was planned.Therefore, the project
was exempted from formal ethics committee approval.
All pregnant women greater than 20-week gestation
referred for public maternity care who resided within the
postcodes 6001–6007, 6147, 6148, 6151, 6152, and 6155 within
the North Metropolitan Health Service of the Western Aus-
tralian Department of Health between July 1, 2010, to June
30, 2014, were included in the audit. Women with a history
of preexisting diabetes mellitus (type 1 or 2) were specifically
excluded from the project.
All women had an OGTT between 24 and 28 weeks of
gestation in accordance with the existing clinical protocol
[11].
The ADIPS 1999 criteria were used to diagnose GDM in
the period from July 1, 2010, to December 31, 2011 [6].Women
had a 75-gram OGTT with glucose samples taken after an
overnight fast and at 2 hr postprandially. GDMwas diagnosed
if the fasting glucose was ≥5.5mmol/L (100mg/dL) and/or
the 2 h glucose was ≥8.0mmol/L (∼145mg/dL) [6].
From January 1, 2012, to June 30, 2014, all patients were
diagnosed with GDM using the IADPSG 2010 diagnostic
criteria [4]. Women had a 75-gram OGTT with glucose
samples taken after an overnight fast and at 1 hr and 2 hr
postprandially.One ormore abnormal valueswere needed for
a diagnosis of GDM to be made: FBG > 5.0mmol/L and/or 1-
hour BSL > 10mmol/L and/or 2-hour BSL ≥ 8.5mmol/L.
Themajority of OGTT in the audit period was performed
at the Western Diagnostics Pathology laboratories. A small
number (2.8%) was performed at other private accredited
pathology providers.
All patients had their weight (kg) and height (m) recorded
at their booking visit to calculate their body mass index
(BMI). Patients with a BMI greater than 40 had their
antenatal care at the localmaternity hospital butwere referred
for delivery to the regional tertiary hospital. These patients
remained within the audit study.
All pregnancies diagnosed with GDM across the audit
period received identical clinical care according to a written
protocol. This involved an initial consultation with a dia-
betic educator, dietician, and obstetric doctor. Patients com-
menced self-monitoring of blood sugar levels and adopted a
diabetic diet. A review visit a fortnight later determined if
medication was required in addition to diet.
Delivery outcomes were entered into a computerized
database called Meditec by attending midwifery staff as part
of routine practice. Delivery outcomes were subsequently
extracted from Meditec, case note audit, and a postnatal
clinical service for all women with GDM conducted by one
author (Julie Quinlivan).
Predefined maternal outcomes were audited. These were
mode of delivery, elective or emergency caesarean section,
estimated blood loss, and 3rd or 4th degree perineal tear.
Predefined newborn outcomes were audited. These were
gestational age at birth, birthweight, birthweight >90th cen-
tile adjusted for gestational age, Apgar at 1 and 5 minutes,
umbilical artery and vein pH, admission to Special Care
Unit, and serious perinatal complications such as still-
birth, neonatal death, or birth trauma including shoulder
dystocia.
A power calculation assumed that the change in incidence
of GDM would be 30%, a conservative estimate based on
the previous Australian and New Zealand studies [7, 8]. The
baseline rate of GDM in the audit region was approximately
3.5%. Assuming a power of 80% and alpha error of 0.05, a
sample of 10,994 women was required across the audit period
to detect a change in incidence from 3.5 to 4.6%.
Data were presented as number and percentage for
the incidence of GDM. Descriptive statistics of predefined
clinical outcomes were compared using Student’s 𝑡-test for
continuous variables and Chi Square test or Fisher exact test
for discrete data. A 𝑝 value of 0.05 was considered significant.
3. Results
Of 10,296 women delivering in the audit period, antenatal
OGTT results could be traced for 10,277 women (99.8%).The
remaining 19 (0.2%) women did not have an antenatal OGTT,
in violation of national clinical protocol. Of these women, 5
attempted an OGTT and were unable to complete the test
due to nausea and/or vomiting.They subsequently declined a
repeat test. The other 14 women either presented for care too
late for testing or declined testing.
Table 1 summarizes the incidence of GDM under the two
diagnostic criteria.The overall incidencewas not significantly
different with 3.4% diagnosed under the ADIPS 1999 criteria
and 3.5% under the IADPSG 2010 criteria. In the subgroup
of 342 women with a BMI > 40 (representing 3.3% of the
study population) the incidence of GDM was 3.7% using
ADIPS 1999 criteria and 8.5% using IADPSG 2010 criteria.
This difference was not statistically significant (𝑝 = 0.11);
however, the audit was not adequately powered to detect a
difference in the subgroup of women with high BMI.
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Table 1: Incidence of GDM under ADIPS 1999 and IADPSG 2010
criteria.
ADIPS IADPSG 𝑝 value
All women 𝑁 = 3,553 𝑁 = 6,724
0.78GDM 121 (3.4%) 236 (3.5%)
No GDM 3,432 (96.6%) 6488 (96.5%)
Women with BMI ≤ 40 𝑁 = 3446 𝑁 = 6489
0.86GDM 117 (3.4%) 216 (3.3%)
No GDM 3,329 (96.6%) 6,273 (96.7%)
Women with BMI > 40 𝑁 = 107 𝑁 = 235
0.11GDM 4 (3.7%) 20 (8.5%)
No GDM 103 (96.3%) 215 (91.5%)
Across the audit period the proportion of women with
GDM who required management with medication (met-
formin or insulin) in addition to diet was not significantly
different (25% in women diagnosed by ADIPS 1999 criteria
and 28% in women diagnosed by IADPSG 2010 criteria,
resp.).
Delivery data for 10,277 (98%) women were available
for audit through Meditec, case note audit, or the postnatal
clinical service.
Table 2 summarizes predefined delivery outcomes. Babies
born to women diagnosed with GDM according to the
IADPSG 2010 criteria had significantly higher umbilical
artery pH (7.28 versus 7.21; 𝑝 = 0.01). They had a significant
lower birthweight (3360 gms versus 3470 gms; 𝑝 = 0.02) and
birthweight above the >90th centile adjusted for gestational
age (11% versus 18%; 𝑝 = 0.04). Other predefined mater-
nal and newborn outcomes were not significantly different
between groups.
4. Discussion
The audit found no significant difference in the incidence of
GDM before and after the introduction of the IADPSG 2010
criteria, with the overall incidence being low at 3.5%. Our
results differ from the previous Australian and New Zealand
studies [7, 8].
One explanation may be that prevalence of GDM in our
region is low compared to many other sites. Our rate of
3.5% contrasts higher background rates in the sites involved
in the HAPO trial where incidences ranged from 8 to 25%
[12]. However, HAPO study sites were specifically included
because of their high rates of GDM. They were tertiary
sites where women with high BMI and other pregnancy
complications were referred for antenatal and delivery man-
agement [5, 12]. Our study was based upon a geographical
region rather than a hospital cohort and thus captured
women of all risk levels, including a majority who were of
“normal” risk, unlike the patient population within a tertiary
centre.
A second explanation for the observed difference in
outcome between our study and previous ones may be
the racial mix of the population. Although our geographic
maternity cohort reflected the wider Australian public mater-
nity cohort in terms of maternal age and parity [13],
racial background was overwhelmingly English speaking
Caucasian.
A third explanation may be due to maternal obesity
levels. Our geographic catchment has a low prevalence of
overweight and obese patients compared tomany sites. Lower
obesity levels mean that the underlying risk of metabolic
hyperglycaemia is lowered. Of note, in our subgroup of
women with a BMI > 40 the incidence of GDM rose from
3.7% to 8.5% under the IADPSG 2010 criteria, more in line
with studies elsewhere [7, 8].
As a secondary consideration, the adoption of the
IADPSG 2010 criteria did not adversely impact upon our
predefined maternal and newborn outcomes. There was a
significant improvement in three newborn outcomes, being
an increase in umbilical artery pH and a reduction in
birthweight and birthweight >90th centile adjusted for ges-
tational age. There were no significant changes in mater-
nal outcomes. This provides reassuring safety data for the
change.
The study had several strengths. Firstly, data were
extracted from a defined geographic region before and after
implementation of the IADPSG 2010 diagnostic criteria.
Secondly, all women received treatment using identical clin-
ical protocols throughout the audit period. Thirdly, there
was high compliance with screening for GDM (99.8%) and
ascertainment of outcome (98% of women). A study limi-
tation is the low background incidence of GDM that limits
generalizability to regions where incidence rates are higher. A
second limitation is that only 3.3% ofwomen presentedwith a
BMI > 40. In this subgroup of women, the incidence of GDM
was higher at 8.5%. Centres where the obstetric population
has a higher incidence of obesity may report an increase in
the incidence in GDM utilising the new diagnostic criteria.
However, it is likely that this reflects a genuine increase in
metabolic pathology, as obesity is amajor risk factor forGDM
and adverse pregnancy outcome [14].
5. Conclusion
The IADPSG used a consensus process to redefine GDM
based on its association with adverse pregnancy outcomes.
There has been controversy about the adoption of the new
guidelines. However, in our audit study of 10,296 women,
we observed no significant increase in the incidence of
GDM. The adoption of the new criteria was associated with
improvements in three newborn outcomes.
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Table 2: Delivery outcomes.
GDM ADIPS
𝑁 = 121
GDM IADPSG
𝑁 = 236
𝑝 value
Maternal outcomes
Maternal age (years)
Mean (sd) 31.0 (5.3) 31.1 (5.6) 0.75
Parity
Median (IQR) 1 (1–2.5) 1 (1–2.5) 0.34
Caesarean section
𝑁 (%) 30 (25%) 64 (27%) 0.64
Blood loss (mL)
Median (IQR) 300 (200–380) 300 (200–400) 0.25
Birth trauma (3rd/4th degree tear)𝑁 (%) 2 (2%) 5 (2%) 1.00
Newborn outcomes
Gestational age (days)
Mean (sd) 274 (7) 275 (6) 0.82
Birthweight (grams)
Mean (sd) 3470 (345) 3360 (321) 0.02
Birthweight >90th centile for gestational age
𝑁 (%) 22 (18%) 25 (12%) 0.04
Apgar 1
Mean (sd) 9 (8.25–9) 9 (9-9) 0.17
Apgar 5
Mean (sd) 9 (8.40–9) 9 (9-9) 0.21
Arterial cord blood
Mean (sd) 7.21 (0.6) 7.28 (0.6) 0.01
Venous cord blood
Mean (sd) 7.33 (0.2) 7.34 (0.2) 0.89
Admission to neonatal nursery𝑁 (%) 14 (12%) 28 (12%) 0.93
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